ZEMA Pharma Consulting ApS: Financial statements 2024
CVR: 42680427
Source: annual report 2024, Danish Business Authority
01/10/2023 – 30/09/2024
ZEMA Pharma Consulting ApS (CVR 42680427) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 130,753 and a net result of DKK -281,625 compared with DKK 812,354 the year before. That is a decrease of 91.1% compared with the year before. Equity in the 2024 report amounted to DKK 571,287. The solvency ratio was 90.3%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 130,753
- Profit/Loss
- DKK -281,625
- Equity
- DKK 571,287
- Total Assets
- DKK 632,672
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 131K | -282K | 571K | 1 |
| 2023 | - | 1.5M | 812K | 853K | 1 |
| 2022 | - | 1.1M | 790K | 830K | 1 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningAbout ZEMA Pharma Consulting ApS
ZEMA Pharma Consulting ApS is a Danish company of the type Anpartsselskab based in Dyssegård, founded in 2021. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The management consists of Mads Torkild Hansen. The company is owned by Mads Torkild Hansen. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 102,227 and a net result of DKK -216,744 compared with DKK -281,625 the year before. Equity in the 2025 report amounted to DKK 354,543.
